Peter Kaiser Sells 3,035 Shares of Ocular Therapeutix (NASDAQ:OCUL) Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Peter Kaiser sold 3,035 shares of the stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $10.77, for a total transaction of $32,686.95. Following the completion of the sale, the insider owned 264,378 shares in the company, valued at $2,847,351.06. This represents a 1.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ocular Therapeutix Trading Up 0.5%

Shares of Ocular Therapeutix stock opened at $10.82 on Friday. Ocular Therapeutix, Inc. has a 1 year low of $6.23 and a 1 year high of $16.44. The company has a debt-to-equity ratio of 0.14, a current ratio of 13.10 and a quick ratio of 13.03. The business has a 50 day moving average price of $9.66 and a 200 day moving average price of $9.16. The company has a market capitalization of $2.38 billion, a P/E ratio of -7.62 and a beta of 0.93.

Ocular Therapeutix (NASDAQ:OCUL) last announced its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.05. The firm had revenue of $13.47 million for the quarter, compared to analysts’ expectations of $13.20 million. Ocular Therapeutix had a negative return on equity of 59.89% and a negative net margin of 579.10%.Ocular Therapeutix’s quarterly revenue was down .1% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.39) EPS. Sell-side analysts anticipate that Ocular Therapeutix, Inc. will post -1.47 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Chardan Capital reiterated a “buy” rating and set a $23.00 price objective on shares of Ocular Therapeutix in a research report on Tuesday, August 4th. Wall Street Zen upgraded shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price target (up from $21.00) on shares of Ocular Therapeutix in a research note on Thursday, June 18th. Zacks Research upgraded shares of Ocular Therapeutix from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 12th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Ocular Therapeutix in a research report on Friday, July 17th. Eleven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $25.75.

Institutional Investors Weigh In On Ocular Therapeutix

A number of hedge funds and other institutional investors have recently made changes to their positions in OCUL. Hilton Head Capital Partners LLC increased its stake in shares of Ocular Therapeutix by 30.4% during the 1st quarter. Hilton Head Capital Partners LLC now owns 4,520 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 1,053 shares during the last quarter. Steward Partners Investment Advisory LLC boosted its position in shares of Ocular Therapeutix by 124.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 2,242 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 1,242 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in Ocular Therapeutix by 1.8% in the second quarter. The Manufacturers Life Insurance Company now owns 72,618 shares of the biopharmaceutical company’s stock valued at $674,000 after purchasing an additional 1,314 shares during the period. Rafferty Asset Management LLC grew its holdings in Ocular Therapeutix by 21.2% in the second quarter. Rafferty Asset Management LLC now owns 13,413 shares of the biopharmaceutical company’s stock valued at $124,000 after purchasing an additional 2,343 shares during the period. Finally, Rockefeller Capital Management L.P. acquired a new position in Ocular Therapeutix during the fourth quarter worth approximately $31,000. Hedge funds and other institutional investors own 59.21% of the company’s stock.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.